Labcorp announces 2026 second quarter results and raises guidance
Revenue increased 5.8% to $3.73 billion, adjusted EPS up 14.9% to $4.99.
See the latest news and media coverage for Labcorp. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical laboratory and drug development services provider
labcorp.comLast updated
In short: Labcorp raised its 2026 financial guidance following strong first-quarter revenue growth and several significant diagnostic expansions.
Revenue increased 5.8% to $3.73 billion, adjusted EPS up 14.9% to $4.99.
It examines the aging workforce, residency gaps, geographic disparities, and how digital pathology enables scalability and remote expertise.
Two peer-reviewed studies published in Nature Communications and Diabetes, Obesity and Metabolism demonstrate potential of MVX and NIS2+ tests.
ColoSense is the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in ...
Labcorp Holdings (LH) Analyst Rating Update On October 13, 2023, Labcorp Holdings (LH) received an...
Labcorp Holdings (LH) Analyst Rating Update On October 13, 2023, Labcorp Holdings (LH) received a...
Labcorp (LH) Q2 2026 earnings call recap: revenue +6%, margin expansion, raised 2026 EPS to $18.10–$...
Track Labcorp and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Labcorp and other trending companies.